Lunaphore is a medtech startup that develops automated solutions, performing immunohistochemistry, based on a unique microfluidic technology.
Lunaphore is disrupting tissue diagnostics field by fundamentally changing the time and resource driven nature of diagnostic assays on tumor sections.
Lunaphore was founded in 2014 by Ata Tuna Ciftlik, Diego Gabriel Dupouy, & Déborah Heintze and is based in Lausanne, Vaud, Switzerland.
Lunaphore has developed a next-generation tissue diagnostics platform for the analysis and classification of tumors and other solid tissues. Based on a proprietary microfluidic chip technology and a bench top device, the platform offers customers unprecedented speed, accuracy and flexibility.
Lunaphore’s unique solution meets today’s needs, where medicine is becoming more personalized and whole panels of biomarkers play an increasing role.
Lunaphore is backed by Eurostars, PHC Holdings Corporation, Venture Kick, OCCIDENT, Zürcher Kantonal Bank, & Redalpine among others. The company raised CHF 23M ($23.54M) in a Series C financing on Feb 06, 2020. This brings Lunaphore's total funding to $40.94M to date.